Clinical Trial Update: Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

View source ↗

Summary

This clinical trial update provides expanded access to MDV3100 (enzalutamide) for patients with progressive castration-resistant prostate cancer who were previo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• MDV3100 (enzalutamide)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Status: APPROVED_FOR_MARKETING